Merck & Co., Inc. (MRK ... Co. for an investigational oral drug for heart disease called HRS-5346. Under the agreement, Merck will have the exclusive rights to develop, manufacture, and ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug ... a Moderate Buy based on 11 Buys ...

The deal gives MSD exclusive rights to ... coronary artery disease, heart attack, stroke, peripheral arterial disease, and aortic stenosis. Currently, there are no approved drugs to reduce levels ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

Rather, it brings with it platform capabilities in formulations of mRNA drugs ... disease applications including heart failure. "The acquisition of Exelead will further enable Merck to capture ...

including 64 million people in the U.S. Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...